dualsubtyp
felin
immunodefici
viru
fiv
vaccin
consist
inactiv
cell
infect
subtyp
petaluma
strain
shizuoka
strain
develop
test
vaccin
efficaci
fiv
infect
specif
pathogen
free
spf
cat
anim
monitor
provir
dna
fivspecif
pcr
fivspecif
antibodi
profil
elisa
virusneutr
assay
addit
blood
challeng
cat
inocul
naiv
spf
cat
confirm
viral
statu
vaccin
cat
cat
immun
petaluma
vaccin
alon
protect
homolog
petaluma
challeng
one
four
cat
protect
heterolog
shizuoka
challeng
importantli
cat
immun
dualsubtyp
vaccin
protect
petaluma
shizuoka
challeng
result
suggest
multisubtyp
vaccin
approach
may
provid
broadspectrum
immun
necessari
vaccin
protect
strain
differ
subtyp
elsevi
scienc
bv
felin
immunodefici
viru
fiv
origin
isol
felin
leukemia
viru
felv
neg
cat
chronic
opportunist
infect
pedersen
et
al
fiv
typic
lentiviru
ultrastructur
morpholog
structur
protein
profil
revers
transcriptas
requir
resembl
human
simian
immunodefici
virus
hiv
siv
fiv
isol
domest
cat
classifi
five
subtyp
design
usa
california
europ
b
japan
usa
except
california
c
canada
japan
e
argentina
compar
sequenc
variabl
region
fiv
env
gene
kakinuma
et
al
pecoraro
et
al
sodora
et
al
hallmark
fiv
infect
domest
cat
immunodefici
syndrom
caus
sever
loss
cell
concomit
declin
ratio
ackley
et
al
barlough
et
al
hoffmannfez
et
al
novotney
et
al
torten
et
al
similar
immunopathogenesi
hiv
place
fiv
infect
cat
import
small
anim
aid
model
test
therapeut
prophylact
approach
gardner
johnson
et
al
pedersen
et
al
varieti
vaccin
approach
evalu
use
fiv
model
includ
fix
infectedcel
inactiv
whole
viru
subunit
recombin
vaccin
gonin
et
al
hofmannlehmann
et
al
hosi
hosi
flynn
hosi
et
al
hosi
et
al
lombardi
et
al
lutz
et
al
matteucci
et
al
siebelink
et
al
verschoor
et
al
yamamoto
et
al
yamamoto
et
al
vaccin
approach
fix
infect
cell
inactiv
whole
viru
vaccin
success
protect
cat
homolog
challeng
yamamoto
et
al
vaccin
prepar
cell
felin
cell
line
chronic
infect
prototyp
subtyp
strain
fiv
petaluma
fivpet
yamamoto
et
al
vaccin
protect
observ
also
challeng
slightli
heterolog
fiv
dixon
fivdix
subtyp
isol
differ
fivpet
amino
acid
sequenc
major
surfac
glycoprotein
env
contrast
protect
achiev
fiv
shizuoka
fivshi
distinctli
heterolog
isol
belong
subtyp
approxim
env
amino
acid
differ
johnson
et
al
furthermor
similar
prepar
inactiv
whole
viru
vaccin
ineffect
subtyp
isol
differ
fivpet
env
amino
acid
sequenc
viru
neutral
profil
hosi
et
al
recent
studi
cat
immun
fix
fiv
mbm
cell
felin
tlymphocyt
line
protect
homolog
challeng
infect
cat
plasma
matteucci
et
al
anoth
studi
cat
immun
three
time
inactiv
whole
viru
vaccin
retain
vaccineinduc
immun
least
month
hosi
et
al
studi
clearli
suggest
vaccin
protect
homolog
challeng
achiev
howev
studi
also
demonstr
difficulti
achiev
vaccin
protect
distinctli
heterolog
strain
one
method
broaden
vaccin
immun
incorpor
protect
epitop
multipl
fiv
subtyp
sinc
protect
epitop
yet
defin
fiv
studi
whole
viru
antigen
two
fiv
subtyp
use
place
end
fix
infect
cell
vaccin
consist
fiv
strain
subtyp
develop
overal
object
studi
evalu
immunogen
protect
efficaci
dualsubtyp
fiv
vaccin
homolog
fiv
challeng
studi
first
step
determin
multisubtyp
vaccin
approach
use
broaden
vaccin
efficaci
cell
use
prepar
petaluma
vaccin
cell
chronic
infect
shizuoka
strain
fivshizuokafet
cell
prepar
shizuoka
vaccin
indirect
membran
immunofluoresc
assay
use
antifiv
cat
serum
show
cell
fivshizuokafet
cell
posit
fiv
antigen
previous
report
yamamoto
et
al
cell
inactiv
paraformaldehyd
h
wash
pb
three
time
prepar
fix
infect
cell
vaccin
fix
infect
cell
petaluma
vaccin
mix
equal
volum
fix
infect
cell
shizuoka
vaccin
use
dualsubtyp
vaccin
singlesubtyp
vaccin
petaluma
strain
fix
infect
cell
use
twentyfour
specificpathogen
free
spf
cat
age
month
divid
three
group
eight
cat
group
challeng
control
group
singlesubtyp
vaccin
petaluma
vaccin
group
dualsubtyp
vaccin
petaluma
shizuoka
vaccin
group
singleand
dualsubtyp
vaccin
group
subcutan
inocul
cell
vaccin
cell
adenylmuramyl
dipeptid
amdp
adjuv
zg
per
dose
byar
allison
three
time
interv
challeng
control
group
inocul
amdp
adjuv
alon
two
week
final
vaccin
cat
intraperiton
challeng
petaluma
strain
shizuoka
strain
anim
infecti
dose
accord
categori
shown
tabl
challeng
virus
petaluma
strain
shizuoka
strain
prolifer
primari
peripher
blood
lymphocyt
pbl
spf
cat
effect
vaccin
challeng
evalu
detect
fiv
provir
dna
pbl
polymeras
chain
reaction
pcr
pbl
x
cell
depend
felin
lymphocyt
cell
line
cell
hohdatsu
et
ai
highli
sensit
fiv
cocultur
day
dna
isol
cultur
cell
use
pcr
fiv
gag
region
posit
amplifi
method
hohdatsu
et
al
pcr
perform
twostep
amplif
use
primer
pair
doubl
pcr
vivo
assay
evalu
effect
vaccin
ml
blood
collect
week
challeng
use
inocul
spf
cat
examin
seroconvers
fiv
antifiv
antibodi
measur
enzymelik
immunosorb
assay
elisa
use
core
transmembran
tm
antigen
petaluma
viru
neutral
nt
test
use
cell
fiv
core
antigen
antigen
electrophoret
purifi
detergentdisrupt
fiv
virion
use
tm
antigen
synthet
peptid
use
amino
acid
sequenc
tm
peptid
qelgcnqnqffc
elisa
perform
method
hohdatsu
et
al
nt
test
perform
use
flatbottom
micropl
nt
titer
petaluma
strain
determin
use
cultur
supernat
cell
shizuoka
strain
use
shizuoka
viru
four
passag
cell
serial
dilut
test
serum
sampl
zl
react
equal
volum
viru
suspens
h
xl
cell
ad
mixtur
allow
react
h
viral
adsorpt
xl
growth
medium
per
well
ad
incub
one
day
incub
half
medium
lwell
replac
fresh
growth
medium
thereaft
growth
medium
similarli
exchang
everi
day
supernat
test
cultur
day
incub
test
elisa
fiv
antigen
detect
kit
idexx
portland
product
fiv
antigen
vaccin
group
cat
show
increas
antibodi
antigen
tm
antigen
three
vaccin
fig
three
vaccin
protect
mean
elisa
od
valu
antigen
tm
peptid
remain
high
least
week
challeng
fig
hand
mean
elisa
od
valu
antigen
tm
peptid
gradual
decreas
cat
group
well
protect
cat
group
fig
l
tabl
show
neutral
antibodi
titer
petaluma
shizuoka
strain
day
challeng
neutral
antibodi
titer
petaluma
strain
cat
except
cat
shizuoka
strain
cat
includ
petaluma
shizuoka
vaccin
group
inactiv
vaccin
deriv
cell
report
ineffect
challeng
shizuoka
strain
amino
acid
sequenc
region
differ
johnson
et
al
studi
inactiv
cell
vaccin
show
protect
challeng
petaluma
viru
homolog
strain
shizuoka
viru
heterolog
strain
howev
inactiv
cell
vaccin
shizuoka
strain
ad
inactiv
cell
vaccin
cell
protect
also
observ
challeng
shizuoka
strain
result
suggest
use
fiv
multisubtyp
vaccin
studi
perform
pcr
frequent
use
evalu
effect
vaccin
serolog
analysi
also
vivo
assay
passag
blood
week
challeng
cat
vivo
assay
indic
presenc
viru
cat
posit
pcr
week
fiv
system
measur
use
cat
time
high
measur
use
felin
tlymphocyt
jk
yamamoto
person
commun
suggest
vivo
assay
sensit
pcr
use
studi
use
evalu
effect
fiv
vaccin
induct
fivspecif
humor
immun
respons
neutral
antibodi
cellmedi
immun
respons
cytotox
lymphocyt
ctl
respons
report
import
protect
fiv
infect
hosi
flynn
yamamoto
et
al
yamamoto
et
al
howev
type
immun
effector
respons
vaccineinduc
protect
observ
studi
remain
unclear
shown
tabl
neutral
antibodi
titer
shizuoka
viru
day
challeng
even
cat
immun
petaluma
shizuoka
vaccin
protect
challeng
shizuoka
viru
correl
neutral
antibodi
titer
neutral
antibodi
petaluma
viru
detect
vaccin
cat
howev
cat
show
neutral
antibodi
titer
also
protect
challeng
petaluma
viru
studi
shown
inconsist
result
correl
protect
fiv
infect
neutral
antibodi
titer
time
challeng
lombardi
et
al
matteucci
et
al
siebelink
et
al
yamamoto
et
al
hosi
flynn
found
protect
challeng
correl
neutral
antibodi
titer
measur
use
crfk
cell
system
measur
nt
assay
base
felin
cell
line
mbm
neutral
antibodi
titer
measur
use
crfk
cell
system
report
higher
measur
use
felin
cell
system
baldinottl
et
al
felin
cell
system
neutral
antibodi
titer
report
depend
passag
histori
viru
use
baldinottl
et
al
though
neutral
antibodi
titer
differ
accord
method
use
protect
fiv
infect
possibl
passiv
antibodi
transfer
suggest
import
humor
immun
fiv
infect
pu
et
al
evalu
relationship
effect
fiv
vaccin
neutral
antibodi
studi
need
effect
differ
neutral
antibodi
measur
system
siv
vaccin
studi
protect
observ
macaqu
immun
siv
grown
human
cell
appear
relat
close
immun
respons
direct
cell
membran
antigen
rather
virusspecif
immun
respons
stott
howev
fiv
vaccin
system
protect
report
result
virusspecif
immun
respons
associ
immun
respons
vaccinederiv
cell
membran
antigen
hosi
et
al
matteucci
et
al
studi
also
antibodi
cell
membran
antigen
well
virusspecif
antibodi
detect
vaccin
data
shown
fivspecif
ctl
activ
detect
week
experiment
fiv
infect
vaccin
cat
protect
challeng
hosi
flynn
song
et
al
yamamoto
et
al
gagspecif
ctl
activ
well
envspecif
ctl
activ
detect
flynn
et
al
hosi
flynn
find
suggest
unlik
neutral
epitop
ctl
epitop
present
fiv
env
region
also
gag
region
gagspecif
ctl
effect
protect
fiv
infect
induct
mark
gagspecif
ctl
activ
may
allow
product
fiv
vaccin
also
effect
infect
fiv
strain
howev
ctl
epitop
result
recoveri
fiv
infect
identifi
sinc
fivspecif
ctl
activ
studi
examin
associ
protect
could
clarifi
conclus
mechan
protect
fiv
inactiv
vaccin
still
unclear
dualsubtyp
vaccin
produc
combin
paraformaldehydefix
cell
infect
petaluma
shizuoka
strain
show
protect
challeng
viru
result
suggest
use
multisubtyp
fiv
vaccin
subtyp
fiv
isol
geographicspecif
select
fiv
strain
multisubtyp
vaccin
consid
districtspecif
may
import
produc
effect
fiv
vaccin
studi
multisubtyp
fiv
vaccin
also
use
develop
multisubtyp
hiv
vaccin
